Final data from the phase 3 ALCANZA study: Brentuximab vedotin (BV) vs physician's choice (PC) in patients (PTS) with CD30‐positive (CD30+) cutaneous T‐cell lymphoma (CTCL) Meeting Abstract
| Authors: | Horwitz, S. M.; Scarisbrick, J.; Prince, H. M.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; Pinter‐Brown, L.; Akilov, O.; Geskin, L.; Sanches, J.; Ortiz‐Romero, P.; Lisano, J.; Brown, L.; Palanca‐Wessels, M. C.; Gautam, A.; Bunn, V.; Little, M.; Dummer, R. |
| Abstract Title: | Final data from the phase 3 ALCANZA study: Brentuximab vedotin (BV) vs physician's choice (PC) in patients (PTS) with CD30‐positive (CD30+) cutaneous T‐cell lymphoma (CTCL) |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 286 |
| End Page: | 288 |
| Language: | English |
| ACCESSION: | 137029555 |
| DOI: | 10.1002/hon.96_2630 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting abstract: 232 -- Accession Number: 137029555 -- Entry Date: In Process -- Revision Date: 20190620 -- Publication Type: Article -- Supplement Title: Jun2019 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
